JP2016530268A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530268A5
JP2016530268A5 JP2016535272A JP2016535272A JP2016530268A5 JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5 JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5
Authority
JP
Japan
Prior art keywords
domain
inhibitor
use according
mammal
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016535272A
Other languages
English (en)
Japanese (ja)
Other versions
JP6618908B2 (ja
JP2016530268A (ja
Filing date
Publication date
Priority claimed from PCT/AU2013/001132 external-priority patent/WO2015024042A1/en
Application filed filed Critical
Priority claimed from PCT/AU2014/000830 external-priority patent/WO2015024060A1/en
Publication of JP2016530268A publication Critical patent/JP2016530268A/ja
Publication of JP2016530268A5 publication Critical patent/JP2016530268A5/ja
Application granted granted Critical
Publication of JP6618908B2 publication Critical patent/JP6618908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016535272A 2013-08-22 2014-08-22 免疫抑制を低減又は軽減するためのcd96阻害抗体又は抗体断片の使用 Active JP6618908B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2013903189A AU2013903189A0 (en) 2013-08-22 Immunomodulator
AU2013903189 2013-08-22
AUPCT/AU2013/001132 2013-10-03
PCT/AU2013/001132 WO2015024042A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
AU2014900741A AU2014900741A0 (en) 2014-03-05 Immunoreceptor modulation for treating cancer and viral infections
AU2014900741 2014-03-05
AU2014901002A AU2014901002A0 (en) 2014-03-21 Immunoreceptor modulation for treating cancer and viral infections
AU2014901002 2014-03-21
PCT/AU2014/000830 WO2015024060A1 (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019205385A Division JP2020059714A (ja) 2013-08-22 2019-11-13 癌及びウイルス感染症を治療するための免疫受容体調節

Publications (3)

Publication Number Publication Date
JP2016530268A JP2016530268A (ja) 2016-09-29
JP2016530268A5 true JP2016530268A5 (enExample) 2017-10-05
JP6618908B2 JP6618908B2 (ja) 2019-12-11

Family

ID=52482836

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016535272A Active JP6618908B2 (ja) 2013-08-22 2014-08-22 免疫抑制を低減又は軽減するためのcd96阻害抗体又は抗体断片の使用
JP2019205385A Pending JP2020059714A (ja) 2013-08-22 2019-11-13 癌及びウイルス感染症を治療するための免疫受容体調節
JP2022012145A Pending JP2022044808A (ja) 2013-08-22 2022-01-28 癌及びウイルス感染症を治療するための免疫受容体調節
JP2023134163A Pending JP2023156487A (ja) 2013-08-22 2023-08-21 癌及びウイルス感染症を治療するための免疫受容体調節

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019205385A Pending JP2020059714A (ja) 2013-08-22 2019-11-13 癌及びウイルス感染症を治療するための免疫受容体調節
JP2022012145A Pending JP2022044808A (ja) 2013-08-22 2022-01-28 癌及びウイルス感染症を治療するための免疫受容体調節
JP2023134163A Pending JP2023156487A (ja) 2013-08-22 2023-08-21 癌及びウイルス感染症を治療するための免疫受容体調節

Country Status (20)

Country Link
US (2) US20160208000A1 (enExample)
EP (1) EP3036258B1 (enExample)
JP (4) JP6618908B2 (enExample)
KR (3) KR20230085220A (enExample)
CN (1) CN105636985A (enExample)
BR (1) BR112016003532A8 (enExample)
CA (1) CA2921774C (enExample)
DK (1) DK3036258T3 (enExample)
ES (1) ES2967538T3 (enExample)
FI (1) FI3036258T3 (enExample)
HK (1) HK1225396A1 (enExample)
HR (1) HRP20231186T1 (enExample)
HU (1) HUE063307T2 (enExample)
MX (1) MX2016002263A (enExample)
MY (1) MY192043A (enExample)
NZ (1) NZ717534A (enExample)
PL (1) PL3036258T3 (enExample)
SG (1) SG11201601283PA (enExample)
SI (1) SI3036258T1 (enExample)
WO (1) WO2015024060A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013398294A1 (en) * 2013-08-22 2016-03-17 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
ES2939084T3 (es) * 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Anti-pd-l1 antibodies
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
EP3664843A1 (en) * 2017-08-11 2020-06-17 BliNK Biomedical SAS Cd96-binding agents as immunomodulators
US20200347130A1 (en) * 2017-11-10 2020-11-05 Jiangsu Hengrui Medicine Co., Ltd. CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220053007A (ko) * 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
EP4034562B1 (en) * 2019-09-27 2025-10-29 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins
EP4052727A4 (en) * 2019-10-30 2023-12-20 University of Tsukuba IMMUNE RESPONSE INHIBITOR
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN116377061B (zh) * 2022-11-28 2024-01-16 中山大学孙逸仙纪念医院 乳腺癌新辅助化疗耐药标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
WO2005107799A1 (ja) * 2004-05-06 2005-11-17 Eisai R & D Management Co., Ltd. 抗Necl-5抗体を有効成分として含む癌治療剤
EP2097535B1 (en) * 2006-12-07 2016-09-21 The Board of Trustees of the Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
SG10202112838YA (en) * 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
US9149544B2 (en) * 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
CN102204901A (zh) * 2010-03-30 2011-10-05 中国科学院上海生命科学研究院 调节免疫分子的试剂和方法
HK1210964A1 (en) * 2012-12-04 2016-05-13 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
CN105378067A (zh) * 2013-05-13 2016-03-02 塞勒克提斯公司 工程化用于免疫治疗的高活性t细胞的方法

Similar Documents

Publication Publication Date Title
JP2016530268A5 (enExample)
JP2016530267A5 (enExample)
Vangelista et al. The expanding therapeutic perspective of CCR5 blockade
Utsunomiya et al. Recent advances in the treatment of adult T‐cell leukemia‐lymphomas
HRP20231186T1 (hr) Modulacija imunoreceptora za liječenje raka i virusnih infekcija
Michlmayr et al. Defining the chemokine basis for leukocyte recruitment during viral encephalitis
WO2014089169A4 (en) Immunotherapy with binding agents
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
JP2017513478A5 (enExample)
NZ601943A (en) Antibodies against cxcr4
JP2018522592A5 (enExample)
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
JP2014530226A5 (enExample)
JP2015535691A5 (enExample)
JP2019520550A5 (enExample)
EA201200795A1 (ru) Связывающие элементы для пептида с5а с высоким ингибирующим действием
MX2017009052A (es) Anticuerpos de unión a april modificados.
MX2021001305A (es) Anticuerpos anti-cxcr2 y usos de los mismos.
JP2014087372A5 (enExample)
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
TN2015000348A1 (en) Antibodies that bind il-23
CN111542546A (zh) 抗lag-3 抗体及其用途
JP2017521445A5 (enExample)